Vincerx Pharma, INC

Vincerx Pharma, Inc. is proceeding with its dissolution and liquidation, urging stockholders to approve the plan to facilitate an estimated distribution of $0.04 to $0.08 per share and potential tax benefits.

Vincerx Pharma plans to delist from Nasdaq, dissolve the company, and liquidate its assets after failing to meet the minimum bid price requirement.

Vincerx Pharma has terminated its merger agreement with QumulusAI and is initiating wind-down activities while exploring asset monetization.

Vincerx Pharma has entered a non-binding letter of intent to merge with QumulusAI, a high-performance computing infrastructure company for artificial intelligence, in a reverse triangular merger.

Vincerx Pharma has terminated its reverse merger term sheet with Oqory, Inc. and is now evaluating strategic alternatives, including a potential wind-down of operations.

Vincerx Pharma has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement of $1.00 per share.

Vincerx Pharma's board of directors has approved a plan to dissolve, liquidate, and wind-up the company due to limited cash resources and the inability to raise capital.

Vincerx Pharma's Q3 2024 report details ongoing clinical trials, financial results, and a focus on advancing their oncology pipeline despite continued operating losses.

Vincerx Pharma's Q2 2024 report details a net loss of $1.8 million, alongside updates on clinical programs and financial activities.

Vincerx Pharma reports a net loss of $12.4 million for the first quarter of 2024, alongside a recent capital raise of $17.8 million.

Vincerx Pharma reports its 2024 10-K filing, highlighting strategic shifts, ongoing losses, and a potential business combination with QumulusAI.

Vincerx Pharma's 2023 10-K filing details the company's clinical-stage pipeline, financial position, and strategic focus on its VersAptx platform.

Vincerx Pharma, Inc. has entered into a non-binding letter of intent with Global Digital Holdings Inc. (QumulusAI) for a proposed business combination via a reverse triangular merger.

Tom Thomas, General Counsel and Chief Legal Officer of Vincerx Pharma, reports the repricing of certain stock options approved by stockholders on August 12, 2024.

CEO Ahmed Hamdy reports adjustments to stock option holdings in Vincerx Pharma, including repricing of existing options.

Alexander Seelenberger, CFO of Vincerx Pharma, reports the repricing of certain stock options approved by stockholders on August 12, 2024.

Raquel E. Izumi, a Vincerx Pharma officer, reported the repricing of certain stock options approved by stockholders on August 12, 2024.

Alexander A. Seelenberger, CFO of Vincerx Pharma, reports the acquisition of stock options.

A pharmaceutical company has again adjourned its special meeting, urging stockholders to approve a dissolution proposal to preserve potential distributions now estimated between $0.03 and $0.07 per share.

A pharmaceutical company has announced its board's approval for dissolution and liquidation, estimating a final distribution to stockholders of $0.04 to $0.08 per share, urging immediate approval to avoid further cost erosion.

Vincerx Pharma, Inc. has adjourned its Special Meeting of Stockholders until July 16, 2025, to secure votes for a crucial dissolution proposal, emphasizing that further delays will diminish potential stockholder distributions.

Vincerx Pharma, Inc. is seeking stockholder approval for its liquidation and dissolution by June 18, 2025, emphasizing that prompt action is critical to preserve any potential, albeit non-significant, distributions and enable capital loss recognition for U.S. holders.

Vincerx Pharma plans to liquidate and dissolve the company after failing to secure financing or strategic partnerships, with stockholders set to vote on the proposal.

Vincerx Pharma and Oqory, Inc. amend their merger term sheet, increasing the minimum value for Vincerx stockholders to $14.16 million and waiving the remaining $500,000 interim financing.

Sage Rhino Capital, LLC has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Vincerx Pharma, Inc., which is noted as pending dissolution.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% in Vincerx Pharma, Inc.'s Common Stock.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in Vincerx Pharma, Inc. as of December 31, 2024.

Prosight Management, LP and affiliated entities have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% in Vincerx Pharma, Inc. as of December 31, 2024, primarily through warrants with conversion restrictions.

An investment group led by Long Focus Capital Management, LLC has filed a final amendment to its Schedule 13G, indicating its beneficial ownership in Vincerx Pharma, Inc. common stock has decreased to 0% as of December 31, 2024.